| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.087 | 0.009 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.08 | 0.01 |